Zobrazeno 1 - 4
of 4
pro vyhledávání: '"James Dunyak"'
Autor:
Sergey Gavrilov, Sergey Aksenov, Gabriel Helmlinger, James Dunyak, Kirill Peskov, Kirill Zhudenkov
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
Therapy optimization remains an important challenge in the treatment of advanced non-small cell lung cancer (NSCLC). We investigated tumor size (sum of the longest diameters (SLD) of target lesions) and neutrophil-to-lymphocyte ratio (NLR) as longitu
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 3, Pp 143-152 (2020)
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 3, Pp 143-152 (2020)
Differences in the effect of gefitinib and chemotherapy on tumor burden in non‐small cell lung cancer remain to be fully understood. Using a Bayesian hierarchical model of tumor size dynamics, we estimated the rates of tumor growth and treatment re
Publikováno v:
Journal of Clinical Oncology. 37:e20697-e20697
e20697 Background: Tumor dynamics have been serving as significant predictors in diagnosis, staging, prognosis and treatment of patients with non-small cell lung cancer (NSCLC). The purpose of this study is to propose a joint model that links the lon
Autor:
Nidal Al-Huniti, Kald Abdallah, Dmitry Onishchenko, Diansong Zhou, Hongmei Xu, Donald R. Stanski, James Dunyak, Gabriel Helmlinger, Helen Tomkinson, Eric Masson
Publikováno v:
Journal of Clinical Oncology. 35:e20606-e20606
e20606 Background: Tumor burden has long been used for the clinical diagnosis, staging, prognosis and treatment of non-small cell lung cancer (NSCLC), as described, for example, in the 7th edition of the AJCC/UICC NSCLC staging guidelines. Previous l